Detalles de la búsqueda
1.
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Lancet;
402(10412): 1541-1551, 2023 10 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37738999
2.
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3â years of treatment in randomized phase III trials.
Br J Dermatol;
190(4): 477-485, 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37950894
3.
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
J Eur Acad Dermatol Venereol;
2024 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38451052
4.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
J Am Acad Dermatol;
88(1): 40-51, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36115523
5.
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Lancet;
397(10273): 475-486, 2021 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33549192
6.
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Lancet;
397(10273): 487-498, 2021 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33549193
7.
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
J Am Acad Dermatol;
84(2): 432-470, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32738429
8.
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
J Am Acad Dermatol;
82(4): 936-945, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31809827
9.
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
J Am Acad Dermatol;
82(1): 161-201, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31703821
10.
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
J Am Acad Dermatol;
82(6): 1445-1486, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32119894
11.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Lancet;
392(10148): 650-661, 2018 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-30097359
12.
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
N Engl J Med;
375(4): 345-56, 2016 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27299809
13.
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.
J Am Acad Dermatol;
81(3): 775-804, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31351884
14.
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.
J Am Acad Dermatol;
80(4): 1073-1113, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30772097
15.
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
J Am Acad Dermatol;
80(4): 1029-1072, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30772098
16.
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
N Engl J Med;
373(2): 136-44, 2015 Jul 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26154787
17.
IL-23 inhibitors for moderate-to-severe psoriasis.
Semin Cutan Med Surg;
37(3): 158-162, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30215632
18.
The Evolving Landscape of Psoriasis Treatment.
Semin Cutan Med Surg;
37(2S): S39-S43, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29614136
19.
Treating to Target-A Realistic Goal in Psoriasis?
Semin Cutan Med Surg;
37(2S): S44-S47, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29614137
20.
Common and Not-So-Common Comorbidities of Psoriasis.
Semin Cutan Med Surg;
37(2S): S48-S51, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29614138